Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:
“Hot off the press!
Nivolumab and lenvatinib in unresectable HCC: the IKF-t006/IMMUNIB translational phs-2 study.
European Journal of Cancer
- Study, but remarkable number of long-term survivors
- ctDNA guided biomarker may help to identify responder
- We need biomarkers in HCC”
Other articles featuring Arndt Vogel on OncoDaily.